Back to the future: host-targeted chemotherapeutics for drug-resistant TB

被引：0
作者：
Napier, Ruth J.
Shinnick, Thomas M.
Kalman, Daniel [1 ]
机构：
[1] Emory Univ, Dept Pathol & Lab Med, Microbiol & Mol Genet Grad Program, Atlanta, GA 30322 USA
来源：
FUTURE MICROBIOLOGY | 2012年 / 7卷 / 04期
关键词：
Abl tyrosine kinase; antibiotic resistance; drug resistance; Gleevec; imatinib; MDR-TB; tuberculosis; XDR-TB; SARCOMA-VIRUS; TYROSINE KINASES; PHILADELPHIA-CHROMOSOME; ABL; IMATINIB; TUBERCULOSIS; GENE; PATHOGENESIS; STREPTOMYCIN; INHIBITION;
D O I：
10.2217/FMB.12.19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：431 / 435
页数：5
相关论文
共 56 条
[51]  
WHO, 2011 2012 TUB GLOB F
[52]  
WHO, 2011, GLOB TUB CONTR
[53]  
WHO, TB GLOB EM
[54]  
*WHO STOP TB PARTN, 2006, GLOB PLAN STOP TB 20
[55]  
World Health Organization, 2008, 4 WHO
[56]   Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis [J].
Yee, D ;
Valiquette, C ;
Pelletier, M ;
Parisien, I ;
Rocher, I ;
Menzies, D .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (11) :1472-1477
123456